with chemotherapy at relapse, was compared with chemotherapy given as adjuvant (Link et al., 1986; Eilber et al., 1987) . Although of slightly different design, these studies have shown a clear benefit in relapse-free survival in favour of the adjuvant chemotherapy group. The long-term survival with intensive adjuvant chemotherapy is best shown by the data from West Germany, where in the COSS 80 study 65% of patients are relapse-free at 5 years (Winkler et al., 1984 (Winkler et al., , 1988 . These data are from a national study, and although there are stringent entry criteria for the trial, the results are more likely to represent the general prognosis than single institution studies. These trials have used chemotherapy based on the T7 and T1O protocol introduced by Rosen et al. (1979 Rosen et al. ( , 1982 . This scheme is complex and was evolved by the Sloan-Kettering group in a series of non-randomised studies in the 1970s (Rosen, 1978 (Rosen, , 1979 . It contains all of the drugs then known to be active in osteosarcoma: high dose methotrexate (HDMTX), doxorubicin, cisplatin and cyclophosphamide, as well as some which were probably of little value (bleomycin and actinomycin). The programme is long (44 weeks), toxic, and relies heavily on HDMTX, especially in the initial stages. The value of HDMTX has been recently reviewed (Green et al., 1988) . It is associated with responses in about 25% of patients with metastatic disease, but has not been demonstrated to add to the activity of multidrug regimens containing doxorubicin and platinum. Its expense constitutes a formidable problem. A recent large randomised trial, conducted by several European groups in collaboration, including the UK Medical Research Council (The European Osteosarcoma Intergroup: EOI) has shown that results apparently comparable to those obtained in COSS80 can be obtained with a much shorter regimen using doxorubicin and cisplatin alone (Bramwell et al., 1988) . Since it is clearly of importance to know whether chemotherapy can be shortened, the collaborative group is now embarked on a randomised comparison of the two drug regimen and the T1O protocol. If equal, this will allow the development of shorter, more intensive, treatments, perhaps incorporating new agents with activity, such as ifosfamide (Brade et al., 1985) .
Clinically and microscopically osteosarcoma frequently responds to chemotherapy given before surgery. Pain diminishes rapidly and the tumour shrinks-often considerably. Easily assessable clinical responses do not always occur, and, in these patients, there is a real danger that surgical removal is being delayed in a tumour which is not controlled and which may metastasise. There are, as yet, no reliable methods of detecting early response or progression. Response of bone marrow disease can be visualised on MRI scanning in leukaemia and other tumours (Cohen et al., 1984) but the role of MRI in defining osteosarcoma response is not yet clear. Pathological responses are often dramatic and Rosen et al. (1979) briefly described a scoring system which was said to correlate with risk of relapse. The EOI pathology group have now introduced a semi-quantitative, reproducible method for scoring response and this will allow multivariate analysis to determine if histological response is a factor of prognostic significance independent of tumour size or histological subtype. It is by no means clear that it is correct to change treatment postoperatively in patients with a poor histological response, to a different regimen from that given preoperatively (Rosen et al., 1982) . It is probably unwise to reserve effective agents such as cisplatin and doxorubicin for those patients showing a poor histological response. A better strategy may be to use the most effective agents in all patients (Winkler et al., 1988) .
Since the long-term survival in unselected cases of operable osteosarcoma is now of the order of 60% it has become difficult to undertake trials with enough power to detect survival improvements smaller than 10-15%. Trials with more than 400-500 patients are impractical in this rare disease. The United Kingdom, through the MRC and UK Childrens' Cancer Study Group, is able to recruit 70 patients a year into treatment trials and, even with collaboration from other European countries, it seems unlikely that this figure will rise above 100. Since it is probable that it will be more difficult to cure patients who are not cured by current treatment, it will take a considerable organisational effort to be able to mount studies of the size necessary to detect further improvements. Future directions will include the development of shorter but more intensive regimens and the definition of the prognostic factors which define patients at high risk of failure of chemotherapy response in whom early surgery is advisable.
In the past 8 years there has been a strong move towards limb-sparing surgery where possible. In the UK the endoprostheses have been custom-made at the Royal National Orthopaedic Hospital at Stanmore. Preoperative chemotherapy allows time to make the prosthesis, and in responding patients makes surgery easier by reducing tumour mass. As specialist surgeons have become more familiar with the approach the indications for conservative surgery have widened and this may mean that more local recurrences will occur. Limb-sparing surgery is especially valuable in children who are near the end of their bone growth in whom a gross disparity in leg length is unlikely. The final length of an arm may be less of a problem compared with the social consequences of amputation of an arm. Endoprosthetic replacement is a major step forward but extremely close collaboration between experienced surgeons and oncologists is essential for best results.
Not all patients developing pulmonary metastases will die. In very selected series, when metastases are completely resected, about 30% of patients will be cured (Goorin et al., 1984) . The difficulty lies in selecting cases for thoracotomy. Patients with late relapse, off treatment, with few metastases will have a reasonable chance of survival. Relapse while on chemotherapy, multiple bilateral metastases and rapidly growing metastases all indicate a poor outlook. The criteria for thoracotomy, the value of second-line chemotherapy and post-thoracotomy lung irradiation have yet to be defined.
